EDITORIAL

Atrial fibrillation ablation in the real world

F R Quinn, A C Rankin

While the potential for curative treatment of atrial fibrillation has generated much interest in the role of catheter ablation, its widespread use has been limited by a number of factors.

The observation in the late 1990s that ectopic beats originating from the pulmonary veins could act as triggers for the initiation of atrial fibrillation (AF) opened up the possibility of curative treatment by catheter ablation. The potential for successful treatment has been confirmed, but the applicability of such complex and invasive procedures to the large number of patients with AF remains uncertain. What is the role of catheter ablation for AF in the “real world”?

EVOLUTION OF TECHNIQUE

The optimal method of catheter ablation for AF has been hotly debated. The initial technique was to identify and ablate the “culprit” focus within the pulmonary vein, but this approach was limited by the complication of pulmonary vein stenosis and the recognition that multiple veins were involved in the majority of patients. The technique evolved to aim for electrical isolation of the pulmonary veins, which can be achieved by segmental ablation guided by potentials from a multipole catheter positioned within the ostium of the vein. Around the same time, an alternative approach was developed, involving more extensive ablation of the left atrium, with wider circumferential lesions around the pulmonary veins, guided by sophisticated three-dimensional electroanatomical mapping. This method alters not only the triggers, but also the substrate for the arrhythmia, and can include additional linear atrial lesions. The initial report of this technique suggested higher success rates than the electrophysiologically guided segmental pulmonary vein isolation. A randomised trial comparing the two methodologies in paroxysmal AF confirmed this improved outcome, with 88% of patients who underwent circumferential ablation free of AF at six months, compared to 67% of those who had segmental isolation. Similar findings were reported in a non-randomised study of consecutive patients, with 75% and 60% of patients free from AF following circumferential and segmental ablation, respectively.

LIMITATIONS OF CATHETER ABLATION FOR AF

The potential for curative treatment of the most common cardiac arrhythmia, with its association with significant morbidity and mortality, has generated much interest in catheter ablation for AF. However, a number of factors have limited its widespread use. Initial enthusiasm was tempered by long procedure times and limited success rates, often with the need for repeat procedures. In addition, it became evident that the technique carried the threat of potentially life-threatening complications, such as cardiac tamponade and embolic stroke. Success rates have improved with the evolution and development of techniques, but more extensive ablation has brought the spectre of new complications, such as atro-oesophageal fistulae. The majority of studies report higher success rates in patients with paroxysmal, compared to persistent, AF. Technology in the field is rapidly advancing, and complication rates may be improved further by having better three-dimensional anatomical information—for example, derived from computed tomography or magnetic resonance imaging—and alternative ablation energy sources such as focused ultrasound.

AF ABLATION IN THE “REAL WORLD”

A recent worldwide survey reported 8745 patients treated at 181 centres. The numbers per year increased from 18 patients in 1995 to 5050 in 2002. The majority underwent segmental pulmonary vein isolation, 27.3% had more than one procedure, and major complications occurred in 6.0%; 52% became asymptomatic, and a further 23.9% were improved by antiarrhythmic drugs. Also of note is the fact that centres which had performed the most procedures tended to have the highest success rates.

Pioneering institutions worldwide have now performed ablation for AF on thousands of patients, but can their results be reproduced in lower volume centres? The short report in this issue of Heart by Pontoppidan et al describes the experience of one such electrophysiology centre. This is a non-randomised observational retrospective study, with all the attendant limitations, but is of interest as their experience reflects the progression of the technique elsewhere. Their initial success rate with segmental pulmonary vein isolation was only 25%, with a further 25% improved on drugs. The rate of freedom from AF rose to 73% when they changed to circumferential ablation, with a reduction in the number of repeat procedures. Cardiac tamponade occurred in 4% with both methods, and one patient had a transient neurological deficit. Another recent report in Heart from a “non-pioneering” centre reported 55% success at six month follow up following a first procedure, in a consecutive series of 100 patients. Cardiac tamponade requiring pericardiocentesis occurred in six patients, right coronary artery embolus in
two, and complete heart block in one. Again, the technique evolved during the study, from targeting only arrhythmogenic veins, to attempting to isolate all four pulmonary veins, and the addition of linear lesions in the atrium. These two studies have demonstrated that the technique of pulmonary vein isolation for AF can be introduced into experienced electrophysiology centres with promising results and a complication rate comparable to that reported in the wider literature.

‘‘RATE VERSUS RHYTHM’’

The benefits of maintaining sinus rhythm have been questioned by the “rate versus rhythm” debate, with evidence of possible harm from a pharmacologically based, rhythm control strategy. However, there is growing evidence that the maintenance of sinus rhythm following catheter ablation for AF can provide clinical and prognostic benefits. A non-randomised study examining outcome in 589 patients following catheter ablation for AF showed improved mortality, morbidity, and quality of life, compared to 582 medically treated patients. Indeed, the overall survival of ablated patients was no different to that of the general population, matched for age and sex. Additionally, a study of ablation in patients with congestive heart failure and atrial fibrillation, the majority of whom were in persistent AF, reported improvements in cardiac function, symptoms and quality of life.

CONCLUSIONS

Curative ablative treatment for AF is a clinical reality, but has its limitations, including failure rates of around 25%, recurrences with the need for repeat procedures, and the potential for serious complications. It demands high levels of expertise, including the transseptal puncture technique and skills in catheter manipulation in the left atrium. There is a requirement for trained support staff, and the procedure is facilitated by expensive modern technology. These considerations will restrict its use to specialist electrophysiology centres. As such, the technique is not currently applicable to the majority of patients with AF, many of whom are frail and elderly. However, it is now appropriate that catheter ablation for AF should be available to treat, and possibly cure, those many patients with troublesome AF in whom medical treatment has failed. This will require the expansion of electrophysiology services in many parts of the world. As techniques continue to evolve, and the understanding of this complex arrhythmia advances, the procedural success and safety may improve making it available to more of our patients.

REFERENCES

Atrial fibrillation ablation in the real world

F R Quinn and A C Rankin

Heart 2005 91: 1507-1508
doi: 10.1136/hrt.2004.059212

Updated information and services can be found at:
http://heart.bmj.com/content/91/12/1507

These include:

References
This article cites 15 articles, 9 of which you can access for free at:
http://heart.bmj.com/content/91/12/1507#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: cardiovascular system (8842)
Clinical diagnostic tests (4779)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/